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ttp://dx.doi.org/10.1016/j.jmoldx.2013.10.003Since 2006, the US Food and Drug Administration, Congress, and other policymakers have explored the
appropriate way to guarantee the clinical and analytical validity of laboratory-developed tests. In the
past, the Association for Molecular Pathology has publicly urged the Food and Drug Administration to
exercise caution in implementing regulatory changes that could potentially hinder innovation or
interfere with the practice of medicine. In 2012, the Association for Molecular Pathology Professional
Relations Committee chose to develop this paper with the goal of outlining the best methods for
ensuring appropriate oversight and validation of molecular diagnostic procedures. At the conclusion of
this process, the workgroup reafﬁrmed the Association’s previous position that the Centers for Medicare
and Medicaid Services Clinical Laboratory Improvement Amendments program can provide the appro-
priate level of oversight for the vast majority of diagnostic tests. (J Mol Diagn 2014, 16: 3e6; http://
dx.doi.org/10.1016/j.jmoldx.2013.10.003)The Association for Molecular Pathology (AMP) believes
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Ferreira-Gonzalez et alpatient management and advance the quality of medical
care. In molecular pathology laboratories, the laboratory
professionals, which include pathologists and doctoral sci-
entists, have used laboratory-developed tests (LDTs) to
enable major advancements in the diagnosis and manage-
ment of a wide range of infectious, and inherited and
oncologic diseases. In addition, laboratory professionals use
LDTs to identify suitable bone marrow donors and engage
in subsequent monitoring of disease course in transplant
recipients. It is difﬁcult to overestimate the key roles that
LDTs play in the medical practice. Without LDTs, many of
our most celebrated medical advances would likely not have
been implemented, to the detriment of our patients.
AMP is a vigorous advocate for the principle that only
high-quality, clinically and analytically valid diagnostic
tests should be used in clinical practice. All laboratories that
perform clinical testing should meet, at a minimum, if not
exceed, Clinical Laboratory Improvement Amendments
(CLIA) standards; adhere to established professional society
and laboratory practice guidelines; and obtain required and
optional certiﬁcations and accreditations as appropriate for
their particular settings. The CLIA program, laboratory
accreditation by professional societies such as the College of
American Pathologists (CAP), and board certiﬁcation and
licensure of laboratory directors and other laboratory
personnel have engendered safe, effective, high quality,
accessible, patient-oriented test services. Supporting this
premise are the recognized proﬁciency testing surveys of the
Centers for Medicare and Medicaid Services (CMS), which
include challenges for the most common tested analytes and
have demonstrated excellent performance of LDTs in the
area of molecular pathology for a decade or more.1,2
Similar to other medical specialties, the pathologists,
molecular geneticists, and other clinical laboratory scientists
draw on their experience and medical and scientiﬁc exper-
tise when they implement a new procedure or diagnostic
approach to improve patient care. Nimble innovation in new
test development is crucial to our ability to respond to
emerging public health challenges. This was evident during
the 2009 H1N1 inﬂuenza outbreak in which laboratory
professionals rapidly developed and validated diagnostic
tests to detect the virus and its spread through the popula-
tion, sometimes in advance of public health laboratories.
The current regulatory oversight system enables pathol-
ogists and other laboratory professionals to rapidly incor-
porate new ﬁndings into practice, and to modify existing
laboratory tests and their usage in accordance with advances
in clinical knowledge. This has allowed timely and appro-
priate introduction of innovative testing into practice, and it
has also helped foster patient access to the most up-to-date
treatment options. The AMP has urged the United States
(US) Food and Drug Administration (FDA) to recognize
the value of the system that has served patients and pro-
viders well over the past 25 years, and to preserve the same
ﬂexibility in any new or modiﬁed approaches to LDT
oversight. The Professional Relations Committee and Board4of Directors of the AMP have reached a consensus on the
following approach to assess the analytical and clinical
validity of complex diagnostic tests. This position statement
applies only to LDTs performed in high complexity CLIA
laboratories.Deﬁning LDTs
One of the challenges in determining the appropriate level
of oversight of diagnostic tests is the variability in how
stakeholders deﬁne LDTs. The FDA considers LDTs to be a
class of in vitro diagnostics that are developed, validated,
and offered within and by a single CLIA-certiﬁed laboratory
using components that are regulated individually by the FDA
as Analyte Speciﬁc Reagents, or other speciﬁc or general
reagents (http://www.fda.gov/MedicalDevices/NewsEvents/
WorkshopsConferences/ucm212830.htm, last accessed
June 15, 2013). AdvaMed, the trade association repre-
senting medical device manufacturers, concurs that LDTs
are medical devices that fall under jurisdiction of the FDA.
AdvaMed believes that the FDA should regulate all
diagnostic tests, arguing that in vitro diagnostic kits and
LDTs present the same risks and beneﬁts for patients
irrespective of their site of development or manufacture.3
By contrast, the American Clinical Laboratory Associa-
tion endorsed a 2011 bill introduced by Congressman
Michael C. Burgess (R-TX26),3 which was entitled the
Modernizing Laboratory Test Standards for Patients Act of
2011 (H.R. 3207). H.R. 3207 deﬁnes LDTs as tests devel-
oped and performed by a clinical laboratory “solely to
furnish clinical laboratory testing services for the purpose of
providing information for the diagnosis, prevention, or
treatment of any disease or impairment of, or the assessment
of the health of, human beings...” The deﬁnition of this bill
further distinguishes LDTs by specifying that they are not
otherwise introduced into interstate commerce.
The CAP has a more nuanced approach to the FDA
regulation of LDTs than the Burgess bill, but shares some
common elements. Importantly, the CAP also believes that
LDTs are fundamentally different from either traditional
medical devices or in vitro diagnostic kits. The CAP con-
siders LDTs to be tests that are developed within a CLIA-
certiﬁed laboratory, used in patient management, and per-
formed by the laboratory in which the test was developed,
which is neither FDA cleared nor approved.4 Further
exploring the existence of two regulatory pathways, the US
Department of Health and Human Services Ofﬁce of the
Inspector General announced in 2013 that it intends to study
the agencies oversight of LDTs and describe the challenges
of regulating LDTs. This report is anticipated in 2014.
Finally, Senator Orrin Hatch (R-UT) has proposed legis-
lation that is supported by some diagnostics companies and
an umbrella organization known as the Coalition for 21st
Century Medicine. The Hatch approach would create a new
category of medical products called advanced personalizedjmd.amjpathol.org - The Journal of Molecular Diagnostics
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be deﬁned as laboratory tests that analyze DNA, RNA,
chromosomes, proteins, or metabolites, or otherwise are
chemosensitivity assays, and are intended to be used for the
diagnosis, prevention, cure, mitigation, or treatment of any
disease or impairment, including the prognosis or prediction
of a treatment or assessment of health. Although all other
types of laboratory tests would also be considered medical
devices, regulators would address APDx differently.
The AMP LDT Working Group considered the preceding
deﬁnitions of LDTs together with other possible approaches.
Along with some of the other stakeholders previously
mentioned, the working group recognized that unlike the
FDA-regulated medical devices, laboratory tests have a
professional interpretive component that offers additional
opportunities to enhance patient care through professional
interpretive judgment. This professional judgment and test
performance intersect at the points of design, development,
validation, and continued improvement of LDTs. Thus, a
surgeon purchases a medical device, such as a stent off-the-
shelf for implantation during surgery. The surgeon trusts
that the product was correctly manufactured for its intended
use. By contrast, a pathologist is involved in designing
LDTs, setting their analytic parameters, and subsequently in
consulting with the ordering physician in determining the
appropriate test(s) to perform for a given patient based on
his/her clinical presentation. The pathologist then interprets
the results of the testing in the context of other medical
information. Consequently, LDTs require a regulatory
pathway that acknowledges these differences from medical
devices and preserves the role of the laboratory professional.
Deﬁning LDPs
To clearly distinguish LDTs from traditional medical devices,
the AMP has proposed the new appellation Laboratory-
Developed Procedure (LDP), formerly referred to as LDTs.
We deﬁne an LDP as follows:
An LDP is a professional service that encompasses and
integrates the design, development, validation, veriﬁcation,
and quality systems used in laboratory testing and inter-
pretative reporting in the context of clinical care.
The professionals who provide these procedures possess
education, training, and national certiﬁcations that enable
them to safely and effectively provide LDPs to patients for
clinical care. Such professionals provide continuous super-
vision and have ongoing involvement in every aspect of the
procedures, which are developed or validated independently
in each CLIA-certiﬁed facility.
This new term, LDP, better represents the nature of com-
plex laboratory testing, which is very much a medical service
provided by appropriately trained and qualiﬁed professionals.
These laboratory professionals include pathologists, geneti-
cists, and other doctoral scientists, and they constantly
address clinical and biological variability that heretofore wasThe Journal of Molecular Diagnostics - jmd.amjpathol.orgnot previously considered or perhaps even imagined. Mo-
lecular testing continues to rapidly increase in complexity,
generating ever-increasing amounts of potentially useful data.
In turn, this enhances the complexity and value of the inter-
pretive component, which is concomitantly becoming the
most professional time-consuming aspect for many tests. This
professional service yields the ﬁnal information that can be
applied by direct caregivers to establish a patient’s diagnosis,
estimate his/her prognosis, and identify optimal, appropriate,
and/or potential treatment options, and more.Position Statement and Speciﬁc
Recommendations: Current CLIA Regulations
Provide Sufﬁcient Oversight for LDPs
The AMP believes that the CLIA program at the CMS is the
appropriate vehicle through which to conduct oversight of the
LDPs. Providers of LDPs are knowledgeable about the CLIA
regulations and understand the CLIA requirements for
demonstrating that analytical validity has been established.
Essentially all molecular LDPs are categorized as high
complexity tests, which are subject to themost stringentCLIA
regulations. These regulations set forth parameters such as
personnel qualiﬁcations, quality control, and quality assess-
ment systems and procedures, and reporting responsibilities.
Under the CLIA regulations, clinical laboratories are
permitted to develop their own tests or LDPs, and can offer
these services as long as the laboratory establishes the
following for each test system: the performance speciﬁcations
for accuracy, precision, analytical sensitivity, analytical spec-
iﬁcity, reportable range of test results, reference intervals, and
any other performance characteristics deemed to be required
for proper test performance. Furthermore, the CLIA regula-
tions incorporate a quality systems approach that addresses the
total test process to ensure accurate, reliable, and timely pro-
cedure results. LDP design, development, and validation are
documented, and importantly the performance is closely
monitored. In addition to these determinations, the laboratory
professionals performing the LDPs are required to set and
document the type and frequency of calibration and requisite
quality control for the entire test system. The documentation
required by CLIA and its deemed entities for quality systems
have proved to be successful for troubleshooting actual, sus-
pected, or potential LDP-related performance issues.
Although the CLIA regulations do not explicitly require
laboratories to verify clinical validity of the LDPs, the
regulations can be read to mandate this. High complexity
laboratories must have a clinical consultant who should be
responsible for consultation regarding the appropriateness of
testing ordered and interpretation of test results.5 This in-
dividual must:
“(b) Be available to assist the laboratory’s clients in
ensuring that appropriate tests are ordered to meet the
clinical expectations; (c) Ensure that reports of test results5
Ferreira-Gonzalez et alinclude pertinent information required for speciﬁc patient
interpretation; and (d) Ensure that consultation is available
and communicated to the laboratory’s clients on matters
related to the quality of the test results reported and their
interpretation concerning speciﬁc patient conditions.”
The CLIA program maintains a registry of laboratories
and their test offerings. However, these data are not publicly
available. To increase transparency in its regulatory process,
the CMS should update its information technology infra-
structure to make this database easily and readily available
to the general public and other stakeholders. Moreover, the
registry should make public information about adverse
events and other signiﬁcant problems that have occurred
within a particular laboratory.
The working group also reafﬁrmed the AMP’s prior po-
sition that some very high-risk tests do require pre-
introduction review by a third party reviewer. The Work-
ing Group deﬁned risk itself as:
The potential for harm to patients due to an incorrect or
misinterpreted result when the test is ordered in a manner
consistent with the laboratory’s claims.
Based on this deﬁnition, the members further deﬁned
LDPs that may require pre-introduction review to be:
Those LDPs for which the consequences of an incorrect
result or incorrect interpretation could lead to serious
morbidity/mortality to the patient or otherwise burden public
health AND which use a methodology that is not well un-
derstood or the results from which are not independently
veriﬁable. Such LDPs would be used to predict risk of or risk
of progression of disease, or patient eligibility for a speciﬁc
therapy to treat a disease that is associated with signiﬁcant
morbidity or mortality, AND; use test methodologies that
involve proprietary algorithms or computations such that6the test results cannot be tied to the methods used and/or do
not allow for interlaboratory comparisons to be performed.
The preceding, exceptionally high,-risk LDPs include
those for which methods or other determinants of results
lack transparency, or assays for which a skilled laboratory
professional cannot independently interpret or assess the
validation of the test or its results. Assays that contain
hidden, or black box algorithms, or use proprietary software
are examples of the types of tests that lack sufﬁcient
transparency for laboratory professionals and ordering
physicians to apply without independent third-party review.
Typically, such LDPs will be offered by a single provider
and there are no proﬁciency tests available. It is essential
that third party reviewers, whether from the FDA or entities
external to it, have sufﬁcient knowledge, familiarity with the
relevant technology, statistical expertise, and access to the
needed data to enable them to adequately evaluate an assay
and ensure both its analytic and clinical validity.References
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